These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29141650)

  • 41. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
    Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
    Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.
    Hammond CJ; Park G; Kady A; Rathod K; Rahman N; Vidal C; Wenzel K; Fishman M
    J Subst Abuse Treat; 2022 Feb; 133():108495. PubMed ID: 34218992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes.
    Young GJ; Hasan MM; Young LD; Noor-E-Alam M
    Subst Use Misuse; 2023; 58(4):512-519. PubMed ID: 36762464
    [No Abstract]   [Full Text] [Related]  

  • 44. High-dose tramadol conversion to buprenorphine-naloxone.
    Kirk JK; Boyd CT; Cassidy-Vu L; McRae LP; Strickland HE; Fagan EB
    J Opioid Manag; 2023; 19(2):187-190. PubMed ID: 37270427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K; Peyton ML; Sumner M
    J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Shelby Clinic Medication-Assisted Treatment for Opioid Addiction.
    Penn CL
    J Ark Med Soc; 2016 Aug; 113(2):30-32. PubMed ID: 30047628
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
    Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
    JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder.
    D'Onofrio G; Edelman EJ; Hawk KF; Chawarski MC; Pantalon MV; Owens PH; Martel SH; Rothman R; Saheed M; Schwartz RP; Cowan E; Richardson L; Salsitz E; Lyons MS; Freiermuth C; Wilder C; Whiteside L; Tsui JI; Klein JW; Coupet E; O'Connor PG; Matthews AG; Murphy SM; Huntley K; Fiellin DA
    JAMA Netw Open; 2023 Apr; 6(4):e235439. PubMed ID: 37017967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
    Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
    Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
    [No Abstract]   [Full Text] [Related]  

  • 52. Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults.
    Arias F; Arnsten JH; Cunningham CO; Coulehan K; Batchelder A; Brisbane M; Segal K; Rivera-Mindt M
    Addict Behav; 2016 Sep; 60():137-43. PubMed ID: 27131800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
    González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
    Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.
    Wong JSH; Nikoo M; Westenberg JN; Suen JG; Wong JYC; Krausz RM; Schütz CG; Vogel M; Sidhu JA; Moe J; Arishenkoff S; Griesdale D; Mathew N; Azar P
    Addict Sci Clin Pract; 2021 Feb; 16(1):11. PubMed ID: 33579359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buprenorphine-naloxone.
    Hu T; Nijmeh L; Pyle A
    CMAJ; 2018 Nov; 190(47):E1389. PubMed ID: 30478217
    [No Abstract]   [Full Text] [Related]  

  • 57. A Nurse Practitioner's Perspective on Prescribing Suboxone for Opioid Use Disorder.
    Moore DJ
    J Addict Nurs; 2018; 29(3):226-229. PubMed ID: 30180012
    [No Abstract]   [Full Text] [Related]  

  • 58. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
    Worley MJ; Shoptaw SJ; Bickel WK; Ling W
    Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.
    Hassan AN; Bozinoff N; Jutras-Aswad D; Socias ME; Stewart SH; Lim R; Le Foll B;
    J Addict Med; 2023 Jan-Feb 01; 17(1):e49-e56. PubMed ID: 35916430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance.
    Mark TL; Hinde JM; Zarkin GA; Parish W; Kluckman M
    J Subst Abuse Treat; 2020 Sep; 116():108062. PubMed ID: 32741503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.